Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
about
Pleiotropic effects of pitavastatinErythrocyte-bound apolipoprotein B in relation to atherosclerosis, serum lipids and ABO blood group.Regulating intestinal function to reduce atherogenic lipoproteins.Erythrocyte-bound apolipoprotein B in atherosclerosis and mortality.Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1.Biomarkers of food intake and metabolite differences between plasma and red blood cell matrices; a human metabolomic profile approach.
P2860
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
@en
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
@nl
type
label
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
@en
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
@nl
prefLabel
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
@en
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
@nl
P2093
P1476
Cell-mediated lipoprotein transport: a novel anti-atherogenic concept.
@en
P2093
A P Rietveld
G J van de Geijn
J W F Elte
J W Janssen
M Castro Cabezas
R van Mechelen
S A Bovenberg
S Martinez Hervas
P356
10.1016/J.ATHEROSCLEROSISSUP.2010.04.003
P577
2010-04-27T00:00:00Z